This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Ubrelvy® Alternatives

Ubrelvy®

(ubrogepant)
Ubrelvy
    Migraine
  • Vyepti®
  • Aimovig®
  • Ajovy®
  • Nurtec ODT®
  • Qulipta®
Prescription Only
Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood vessel dilation, and inflammation. Ubrelvy is well-tolerated, with less than 5% of individuals reporting side effects such as nausea, somnolence, and dry mouth. Ubrelvy does not prevent migraines. Ubrelvy is FDA approved for the following indications: Migraine.

Emgality®

(Galcanezumab)
Emgality
    Migraine
  • Vyepti®
  • Aimovig®
  • Ajovy®
  • Nurtec ODT®
  • Qulipta®
Prescription Only
Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be used to treat cluster headaches during a cluster headache period. The most frequently reported side effect is injection site reactions. Additionally, there are no known drug interactions with Emgality. Emgality is FDA approved for the following indications: Migraine and Cluster Headaches.

Dosage & Administration

Administration
Oral
Subcutaneous
Dosing
50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.
Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly.
Latin Shorthand
50 mg PRN or 100 mg PNR. Severe Renal Impairment: 50mg.
240 mg LD (120 mg x 2) then 120 mg/mo.

Financial Assistance

Copay
$0
$0
Annual Cap
Maximum savings of $50 per pill for up to 13 prescription fills.
$4,900
Assistance Expiration
13 prescription fills
12 months
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Ubrelvy® vs. Vyepti®
  • Ubrelvy® vs. Aimovig®
  • Ubrelvy® vs. Ajovy®
  • Ubrelvy® vs. Nurtec odt®
  • Ubrelvy® vs. Qulipta®

Relevant Resources

Emgality
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Ubrelvy
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.